{"id":11420,"date":"2017-02-21T14:17:04","date_gmt":"2017-02-21T13:17:04","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2021\/biotech-company-oncgnostics-receives-one-million-euros-after-crowdfunding-campaign\/"},"modified":"2017-02-21T14:17:04","modified_gmt":"2017-02-21T13:17:04","slug":"biotech-company-oncgnostics-receives-one-million-euros-after-crowdfunding-campaign","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2017-en\/biotech-company-oncgnostics-receives-one-million-euros-after-crowdfunding-campaign\/","title":{"rendered":"Biotech company oncgnostics receives one million euros after crowdfunding campaign"},"content":{"rendered":"

The biotech com\u00adpany oncg\u00adnos\u00adtics GmbH (www.oncgnostics.com), provider of the cer\u00advi\u00adcal can\u00adcer test \u201cGyn\u00adTect\u201d, ends its crowd\u00adin\u00advest\u00ading cam\u00adpaign on Seed\u00admatch very suc\u00adcess\u00adfully. Even before the end of the invest\u00adment period of 60 days, the fund\u00ading tar\u00adget of 500,000 euros was reached at the end of Sep\u00adtem\u00adber 2016. The result is pos\u00adi\u00adtive in another respect, as beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen GmbH (bm|t) increases its invest\u00adment with an invest\u00adment of the same amount. oncg\u00adnos\u00adtics will receive a total of one mil\u00adlion euros for fur\u00adther research, devel\u00adop\u00adment and inter\u00adna\u00adtional sales expan\u00adsion after the suc\u00adcess\u00adful con\u00adclu\u00adsion of the campaign.<\/strong>
\nFor its cer\u00advi\u00adcal can\u00adcer test Gyn\u00adTect, the com\u00adpany oncg\u00adnos\u00adtics launched a crowd\u00adin\u00advest\u00ading cam\u00adpaign on the Seed\u00admatch plat\u00adform (www.seedmatch.com\/oncgnostics)<\/a> last sum\u00admer. The fund\u00ading thresh\u00adold of 100,000 euros was already exceeded within the first twelve hours of the cam\u00adpaign launch, and on 26 Sep\u00adtem\u00adber the fund\u00ading tar\u00adget was reached at 500,000 euros.
\n\u201cWe are very pleased that we were able to con\u00advince so many peo\u00adple about Gyn\u00adTect,\u201d says Dr Alfred Hansel, CEO of oncg\u00adnos\u00adtics. \u201cSuch a test meets the need of women and doc\u00adtors for quick cer\u00adtainty, because many have a friend in their cir\u00adcle of acquain\u00adtances who has already expe\u00adri\u00adenced such a sit\u00adu\u00ada\u00adtion and there\u00adfore know how stress\u00adful such a time is.\u201d
\nGyn\u00adTect can quickly and reli\u00adably clar\u00adify whether a patient actu\u00adally has or has cer\u00advi\u00adcal can\u00adcer that needs to be treated. This makes risk assess\u00adment dur\u00ading cer\u00advi\u00adcal can\u00adcer screen\u00ading much eas\u00adier: Unnec\u00ades\u00adsary, pre\u00adma\u00adture oper\u00ada\u00adtions can be avoided and the chances of early, suc\u00adcess\u00adful treat\u00adment mea\u00adsures can be increased.<\/p>\n

Bet\u00adter med\u00adical care and increas\u00ading demand<\/strong>
\nDue to bet\u00adter access to med\u00adical care and the steadily increas\u00ading edu\u00adca\u00adtion in screen\u00ading options, women are becom\u00ading more inter\u00adested in tests like Gyn\u00adTect. They are relieved of the fears caused by unclear find\u00adings from the cur\u00adrent early detec\u00adtion of cer\u00advi\u00adcal can\u00adcer, and in return are guar\u00adan\u00adteed quick cer\u00adtainty and some\u00adtimes even spared unnec\u00ades\u00adsary operations.
\nThis poten\u00adtial is not only seen by the 429 Seed\u00admatch investors, but also by the ven\u00adture cap\u00adi\u00adtal com\u00adpany beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen GmbH (bm|t), which had already announced at the start of the cam\u00adpaign that it wanted to invest the same amount as the crowd. bm|t (www.bm\u2011t.de)<\/a> has been a share\u00adholder and financ\u00ading part\u00adner in oncg\u00adnos\u00adtics since the end of 2014.
\n\u201concg\u00adnos\u00adtics oper\u00adates in a mar\u00adket with a high, con\u00adstantly grow\u00ading demand for inno\u00adv\u00ada\u00adtive diag\u00adnos\u00adtics: Gyn\u00adTect has a high mar\u00adket poten\u00adtial in the bil\u00adlion euro range. In addi\u00adtion, fur\u00adther research in related areas will expand the can\u00adcer test port\u00adfo\u00adlio. There\u00adfore, we invest in the Thuringian com\u00adpany with great con\u00adfi\u00addence,\u201d says Udo Werner, Man\u00adag\u00ading Direc\u00adtor of bm|t.
\nIn total, oncg\u00adnos\u00adtics will thus receive an invest\u00adment of one mil\u00adlion euros. Among other things, the money will be used for two clin\u00adi\u00adcal studies.<\/p>\n

Future developments<\/h3>\n

The detec\u00adtion of spe\u00adcific epi\u00adge\u00adnetic mark\u00aders is not lim\u00adited to appli\u00adca\u00adtions in cer\u00advi\u00adcal can\u00adcer diag\u00adnos\u00adtics. oncg\u00adnos\u00adtics is also work\u00ading with clin\u00adi\u00adcal part\u00adners to develop tests for other can\u00adcers. For exam\u00adple, oncg\u00adnos\u00adtics is work\u00ading on the val\u00adi\u00adda\u00adtion of mark\u00aders for head and neck tumours in a coop\u00ader\u00ada\u00adtion with the ENT clinic of the Uni\u00adver\u00adsity Hos\u00adpi\u00adtal Jena. In addi\u00adtion, oncg\u00adnos\u00adtics would like to improve the early detec\u00adtion of ovar\u00adian can\u00adcer as well. \u201cUnfor\u00adtu\u00adnately, the screen\u00ading meth\u00adods for ovar\u00adian can\u00adcer are cur\u00adrently hardly sat\u00adis\u00adfac\u00adtory. Although there are a few iso\u00adlated mark\u00aders that are used for this pur\u00adpose, they have no real ben\u00ade\u00adfit because they can only be found in acute cases when it is often already too late,\u201d says Dr Mar\u00adtina Schmitz, Man\u00adag\u00ading Direc\u00adtor and Head of Lab\u00ado\u00adra\u00adtory at oncgnostics.<\/p>\n","protected":false},"excerpt":{"rendered":"

The biotech com\u00adpany oncg\u00adnos\u00adtics GmbH (www.oncgnostics.com), provider of the cer\u00advi\u00adcal can\u00adcer test \u201cGyn\u00adTect\u201d, ends its crowd\u00adin\u00advest\u00ading cam\u00adpaign on Seed\u00admatch very suc\u00adcess\u00adfully. Even before the end of the invest\u00adment period of 60 days, the fund\u00ading tar\u00adget of 500,000 euros was reached at the end of Sep\u00adtem\u00adber 2016. The result is pos\u00adi\u00adtive in another respect, as beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcringen [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[146],"tags":[],"class_list":["post-11420","post","type-post","status-publish","format-standard","hentry","category-2017-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11420"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11420\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}